ERBB2 and sarcoma: Also, the expression of ADC targets including ERBB2/HER2 in sarcomas remains underreported, preventing the development of ADCs such as T-DXd in this rare and heterogeneous family of tumours, whereas their use could represent a major therapeutic opportunity.